Literature DB >> 2416496

Systemic immune response of patients with active pulmonary sarcoidosis.

R P Baughman, P E Hurtubise.   

Abstract

Twenty-two patients with active pulmonary sarcoidosis had the subpopulations of the lymphocytes in the bronchoalveolar lavage (BAL) fluid measured. All 12 with hypergammaglobulinaemia had a T4/T8 ratio of greater than 2.0 and five of 10 without hypergammaglobulinaemia had a ratio less than 2.0 (chi 2 = 5.18, P less than 0.025). When an increased number of T4 lymphocytes was present in the BAL fluid, there was a significant decrease in the absolute number of T4 lymphocytes in the peripheral blood (chi 2 = 6.84, P less than 0.01). The number of T4 lymphocytes in the BAL fluid correlated with the subsequent response to daily steroid therapy for 2 months, as assessed by improvement in vital capacity (r = 0.89, P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416496      PMCID: PMC1577287     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Lymphocyte subpopulations in sarcoidosis: correlation with disease aetivity and duration.

Authors:  R P Daniele; D T Rowlands
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391

Review 2.  Sarcoidosis.

Authors:  D N Mitchell; J G Scadding
Journal:  Am Rev Respir Dis       Date:  1974-12

3.  The present status of treatment of pulmonary sarcoidosis: a house divided.

Authors:  R A DeRemee
Journal:  Chest       Date:  1977-03       Impact factor: 9.410

Review 4.  Disturbances of lymphocyte circulation and mobilization in granulomatous disorders of the lymphoid system.

Authors:  W E Bullock; P E Evans; C Wyatt; S Vergamini
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

5.  The relationships between noninvasive explorations in pulmonary sarcoidosis of recent origin, as shown in bronchoalveolar lavage, serum, and pulmonary function tests.

Authors:  D Valeyre; G Saumon; D Bladier; J Amouroux; J Pré; J P Battesti; R Georges
Journal:  Am Rev Respir Dis       Date:  1982-07

6.  The effect of aging on human serum immunoglobulin concentrations.

Authors:  C E Buckley; F C Dorsey
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

7.  Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Predicting response to therapy.

Authors:  R P Baughman; M Fernandez; C H Bosken; J Mantil; P Hurtubise
Journal:  Am Rev Respir Dis       Date:  1984-05

Review 8.  Immunologic abnormalities in sarcoidosis.

Authors:  R P Daniele; J H Dauber; M D Rossman
Journal:  Ann Intern Med       Date:  1980-03       Impact factor: 25.391

9.  Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes.

Authors:  G W Hunninghake; R G Crystal
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

10.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity.

Authors:  G W Hunninghake; R G Crystal
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

View more
  4 in total

1.  Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations.

Authors:  Nadera J Sweiss; Rafah Salloum; Seema Gandhi; Seema Ghandi; Maria-Luisa Alegre; Ray Sawaqed; Maria Badaracco; Kenneth Pursell; David Pitrak; Robert P Baughman; David R Moller; Joe G N Garcia; Timothy B Niewold
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

2.  Functional immunoregulatory T-cell abnormalities in cystic fibrosis patients.

Authors:  N Lahat; J Rivlin; T C Iancu
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

3.  T Lymphocyte Maturation Profile in the EBUS-TBNA Lymph Node Depending on the DLCO Parameter in Patients with Pulmonary Sarcoidosis.

Authors:  Elżbieta Rutkowska; Iwona Kwiecień; Joanna Bednarek; Rafał Sokołowski; Agata Raniszewska; Karina Jahnz-Różyk; Piotr Rzepecki
Journal:  Cells       Date:  2021-12-02       Impact factor: 6.600

4.  Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis.

Authors:  Susanna Kullberg; Natalia V Rivera; Johan Grunewald; Anders Eklund
Journal:  BMJ Open Respir Res       Date:  2021-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.